New Alzheimer's Drug Approval Expands Treatment Options — and Creates Coverage Questions

Health Affairs' Jeff Byers welcomes Senior
Editor Leslie Erdelack to the program to discuss
FDA's recent approval of an Alzheimer's treatment drug, Lilly’s
Kisunla, how private insurers and Medicare may cover the drug,
and the emerging new class of drugs surrounding Alzheimer's
treatment.


We announced the winner for our You're A Health Policy Wonk If...
contest this week!


Until July 20, we are having a flash sale
on Health
Affairs Insider
membership. Use the code HealthWonkLife for
$30 off the normal Insider price.



Check out our Request For Abstracts page for the April 2025 theme
issue focusing on Food, Nutrition, and Health.



Related Articles:


Approval of Newest Alzheimer’s Drug Will Accelerate New Era
of Treatment by Peter Loftus and Joseph Walker
(Wall Street Journal)

Press Release: Lilly's Kisunla Approved by the FDA for
the Treatment of Early Symptomatic Alzheimer's Disease